licensing opportunities

Oct 02, 2024

Rheumatoid arthritis is a chronic autoimmune disease that wreaks havoc on the joints, causing progressive and destructive polyarthritis. According to the World Health Organization, approximately 18 million people globally live with this condition, with about 1.5 million cases reported in the U.S. Characterized by r...

Sep 04, 2024

Nonalcoholic Steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by liver inflammation and damage due to fat accumulation in the liver. Unlike simple fatty liver, NASH can progress to more serious conditions such as fibrosis, cirrhosis, and even liver failure. This chr...

Aug 18, 2024

"Research is the only hope for families affected by Duchenne muscular dystrophy, and every step forward is a step closer to a cure." Duchenne Muscular Dystrophy (DMD) is a severe form of muscular dystrophy characterized by progressive muscle degeneration and weakness. It is a rare disorder, but it is one of th...

Nov 24, 2017

Cluster of differentiation 40 or CD40 is a co-stimulatory protein found on the antigen presenting cells of the immune system. Agonistic CD40 molecules which include monoclonal antibodies (mAb) offer a new therapeutic option with the potential to generate anticancer immunity by various mechanisms. CD40 is a TNF recep...

Nov 10, 2017

Takeda and Portal Instruments partner to bring about needle-free form of drug delivery Takeda Pharmaceutical and Portal Instruments have partnered with a deal worth $100 million to develop a needle-free drug delivery device and increase patient compliance rates for biologic medicines manufactured by the former compa...

Oct 10, 2017

Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arg...

Sep 19, 2017

Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial investigating TS01, which is a new-generation clot-dissolving therapy for the treatment of clot-induced diseases like i...

Sep 15, 2017

Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights’ platform- Be...

Feb 16, 2017

Mead Johnson Acquired By Reckitt Benckiser for $16.6 Billion Mead Johnson Nutrition Company (MJN), the manufacturer of infant formula and nutritional supplements, has agreed to be acquired by Britain's Reckitt Benckiser Group plc in a deal that values the former's equity at $16.6 billion. Mead Johnson shareholders w...

Feb 07, 2017

FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC Bristol-Myers Squibb’s Opdivo injection (nivolumab) has been approved by U.S. FDA for intravenous use in previously treated, locally advanced or metastatic urothelial carcinoma (mUC), a type of bladder cancer. This indication is approved based on tumo...